On August 10, Teledyne Technologies and Varex Imaging (hereinafter‑referred to as "Varex") jointly announced that they had signed a definitive acquisition agreement. Teledyne will acquire all outstanding common shares of Varex at a cash price of $18.90 per share.
After factoring in Varex’s equity‑based incentive awards and net debt as of April 3, 2026, the total transaction value stands at approximately US$1.1 billion (roughly 7.4 billion‑yuan).
Following the transaction, a brand‑new integrated upstream industry giant will emerge within the sector.
The transaction is an all‑cash deal. The acquisition consideration represents a substantial premium over Varex’s secondary‑market share price. Upon the announcement, the capital market responded positively right away. As of August 10 (Eastern Time), Varex closed at $18.46, marking a 48.75‑percent surge.
Pursuant to the agreement between both parties, the transaction is expected to close in early‑2027. Completion of the deal is subject to customary closing conditions for mergers and acquisitions, including regulatory approvals from multiple jurisdictions and approval by shareholders at Varex’s general meeting.
Upon completion of the merger, Varex’s existing businesses‑‑including X‑ray tubes, assorted detectors, high‑voltage components and imaging software‑‑will be fully integrated into the Teledyne group. The two companies will achieve full alignment of technologies, sales channels and R‑D resources, officially establishing an integrated upstream‑component platform spanning X‑ray emitters, detectors, supporting hardware and imaging algorithms.
Teledyne described the acquisition as a strategic fit, stating that the two‑company customer bases overlap, yet their product lines are "uniquely complementary with minimal overlap", and the takeover can fill relevant market gaps.
Varex also expressed strong confidence in the transaction. Sunny Sanyal, its President, Chief Executive Officer and Director, commented, “Joining Teledyne marks a highly‑significant new chapter for Varex.” “Our X‑ray technology can be seamlessly incorporated into Teledyne’s overall product portfolio. Leveraging its resource advantages, we are able to accelerate the market penetration of high‑end imaging solutions and expedite the research‑and‑development progress of next‑generation products.”
In terms of service‑side advisors, Evercore acted as the exclusive financial advisor to Varex, while Orrick handled its legal‑related matters. Teledyne retained two law‑firms, Latham & Watkins and McGuireWoods, to jointly oversee the legal procedures for the transaction.
According to public information, Teledyne is a world‑renowned manufacturer of precision sensors, imaging equipment and electronic components, with its businesses spanning healthcare, aerospace, industrial inspection, precision instrumentation and other sectors.
In 2011, Teledyne entered the healthcare sector officially through the acquisition of Teledyne DALSA. At that time, the company was developing low‑dose, high‑resolution X‑ray detectors based on CMOS technology. In 2017, Teledyne expanded its medical‑business footprint further by acquiring Teledyne e2v.
At present, Teledyne’s medical‑business segment boasts X‑ray tubes, flat‑panel detectors, photon‑counting detectors and a full range of connection and control accessories. Its products are widely deployed in diagnostic medical imaging, industrial non‑destructive testing, security screening, vehicle‑inspection systems and diverse analysis‑and‑measurement fields.
It should be noted that Teledyne’s medical‑imaging business is confined to back‑end detection devices and vacuum electronic components for radiotherapy. The company has never ventured into essential X‑ray tubes used in DR, fluoroscopy and CT equipment, which prevents it from delivering a complete set of upstream imaging solutions for original‑equipment manufacturers.
Targeted by Teledyne, Varex commands an unassailable leadership standing within the global X‑ray‑imaging‑component industry. Spun off from Varian Medical Systems in 2017, Varex has evolved into the world’s largest independent supplier of X‑ray imaging components backed by more than 70 years of technical heritage. It has built‑up insurmountable competitive moats across numerous market segments.
Relevant statistics indicate that Varex held a 35‑percent share of the global medical X‑ray tube market and a 28‑percent market share in the medical imaging‑component sector in 2025. Its market share reaches as high as 42 % within the high‑end CT tube segment.Eighteen out of the world’s top‑20 medical‑device manufacturers name Varex as their key supplier. The enterprise serves as a core‑component vendor for multinational imaging giants including Siemens Healthineers, Philips, GE Healthcare and Canon Medical Systems.
It should be pointed out that despite Varex possessing top‑tier hardware technologies, its growth ceiling has emerged due to constraints including limited capital scale as an independent enterprise, client‑mix structure, geopolitical‑trade pressures and its single‑industry‑chain positioning. Consequently, being acquired by a large‑scale conglomerate such as Teledyne stands as an optimal option for Varex to break through its development bottlenecks.
——
As CEO Sunny Sanyal remarked, the transaction will not only deliver considerable takeover premiums to shareholders. After gaining access to Teledyne’s industrial‑platform resources, Varex can make up for its shortcomings in capital, algorithms and downstream‑end collaboration backed by abundant capital, cross‑disciplinary technology reserves and worldwide channel resources, and accelerate the commercial roll‑out of advanced imaging solutions.
Upon the completion of resource integration between the two parties, the industry will welcome a new‑era integrated powerhouse boasting full‑stack capabilities for the transmitter end, detector end, as‑well‑as supporting hardware and software.
